327 related articles for article (PubMed ID: 23392469)
21. Robust Reconstitution of Tuberculosis-Specific Polyfunctional CD4+ T-Cell Responses and Rising Systemic Interleukin 6 in Paradoxical Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome.
Ravimohan S; Tamuhla N; Nfanyana K; Steenhoff AP; Letlhogile R; Frank I; MacGregor RR; Gross R; Weissman D; Bisson GP
Clin Infect Dis; 2016 Mar; 62(6):795-803. PubMed ID: 26611774
[TBL] [Abstract][Full Text] [Related]
22. A pilot study to assess inflammatory biomarker changes when raltegravir is added to a virologically suppressive HAART regimen in HIV-1-infected patients with limited immunological responses.
Lichtenstein KA; Armon C; Nagabhushanam V; Efaw BJ; Frazer-Abel A; Hiserote ME; Alam R
Antivir Ther; 2012; 17(7):1301-9. PubMed ID: 22948290
[TBL] [Abstract][Full Text] [Related]
23. Changes in CD4+ and CD8+ T cell subsets in response to highly active antiretroviral therapy in HIV type 1-infected patients with prior protease inhibitor experience.
Gray CM; Schapiro JM; Winters MA; Merigan TC
AIDS Res Hum Retroviruses; 1998 May; 14(7):561-9. PubMed ID: 9591710
[TBL] [Abstract][Full Text] [Related]
24. HCV-specific T-cell responses in HIV/hepatitis C virus-coinfected patients on highly active antiretroviral therapy are comparable to those observed in hepatitis C virus-monoinfected individuals.
Rallón NI; Soriano V; Restrepo C; García-Samaniego J; Labarga P; López M; Peris A; González-Lahoz J; Benito JM
J Acquir Immune Defic Syndr; 2011 May; 57(1):1-8. PubMed ID: 21786458
[TBL] [Abstract][Full Text] [Related]
25. Visceral leishmaniasis as an independent cause of high immune activation, T-cell senescence, and lack of immune recovery in virologically suppressed HIV-1-coinfected patients.
Casado JL; Abad-Fernández M; Moreno S; Pérez-Elías MJ; Moreno A; Bernardino JI; Vallejo A
HIV Med; 2015 Apr; 16(4):240-8. PubMed ID: 25604328
[TBL] [Abstract][Full Text] [Related]
26. Dominant enrichment of phenotypically activated CD38(+) HLA-DR(+) CD8(+) T cells, rather than CD38(+) HLA-DR(+) CD4(+) T cells, in HIV/HCV coinfected patients on antiretroviral therapy.
d'Ettorre G; Ceccarelli G; Serafino S; Giustini N; Cavallari EN; Bianchi L; Pavone P; Bellelli V; Turriziani O; Antonelli G; Stroffolini T; Vullo V
J Med Virol; 2016 Aug; 88(8):1347-56. PubMed ID: 26765625
[TBL] [Abstract][Full Text] [Related]
27. Interleukin-37 Expression Is Increased in Chronic HIV-1-Infected Individuals and Is Associated with Inflammation and the Size of the Total Viral Reservoir.
Højen JF; Rasmussen TA; Andersen KL; Winckelmann AA; Laursen RR; Gunst JD; Møller HJ; Fujita M; Østergaard L; Søgaard OS; Dinarello CA; Tolstrup M
Mol Med; 2015 Apr; 21(1):337-45. PubMed ID: 25879630
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of the impact of highly active antiretroviral therapy on immune recovery in antiretroviral naive patients.
Al-Harthi L; Voris J; Patterson BK; Becker S; Eron J; Smith KY; D'Amico R; Mildvan D; Snidow J; Pobiner B; Yau L; Landay A
HIV Med; 2004 Jan; 5(1):55-65. PubMed ID: 14731171
[TBL] [Abstract][Full Text] [Related]
29. Reconstitution of intestinal CD4 and Th17 T cells in antiretroviral therapy suppressed HIV-infected subjects: implication for residual immune activation from the results of a clinical trial.
d'Ettorre G; Baroncelli S; Micci L; Ceccarelli G; Andreotti M; Sharma P; Fanello G; Fiocca F; Cavallari EN; Giustini N; Mallano A; Galluzzo CM; Vella S; Mastroianni CM; Silvestri G; Paiardini M; Vullo V
PLoS One; 2014; 9(10):e109791. PubMed ID: 25340778
[TBL] [Abstract][Full Text] [Related]
30. Evaluating the impact of hepatitis C virus (HCV) on highly active antiretroviral therapy-mediated immune responses in HCV/HIV-coinfected women: role of HCV on expression of primed/memory T cells.
Al-Harthi L; Voris J; Du W; Wright D; Nowicki M; Frederick T; Landay A; Kovacs A
J Infect Dis; 2006 May; 193(9):1202-10. PubMed ID: 16586355
[TBL] [Abstract][Full Text] [Related]
31. Factors influencing the normalization of CD4+ T-cell count, percentage and CD4+/CD8+ T-cell ratio in HIV-infected patients on long-term suppressive antiretroviral therapy.
Torti C; Prosperi M; Motta D; Digiambenedetto S; Maggiolo F; Paraninfo G; Ripamonti D; Cologni G; Fabbiani M; Caputo SL; Sighinolfi L; Ladisa N; El-Hamad I; Quiros-Roldan E; Frank I
Clin Microbiol Infect; 2012 May; 18(5):449-58. PubMed ID: 21919996
[TBL] [Abstract][Full Text] [Related]
32. Maximum suppression of HIV replication leads to the restoration of HIV-specific responses in early HIV disease.
Al-Harthi L; Siegel J; Spritzler J; Pottage J; Agnoli M; Landay A
AIDS; 2000 May; 14(7):761-70. PubMed ID: 10839583
[TBL] [Abstract][Full Text] [Related]
33. HIV-1-infected children on HAART: immunologic features of three different levels of viral suppression.
Zaccarelli-Filho CA; Ono E; Machado DM; Brunialti M; Succi RC; Salomão R; Kallás EG; de Moraes-Pinto MI
Cytometry B Clin Cytom; 2007 Jan; 72(1):14-21. PubMed ID: 17041945
[TBL] [Abstract][Full Text] [Related]
34. Impact of hepatitis C virus coinfection on T-cell dynamics in long-term HIV-suppressors under combined antiretroviral therapy.
Zaegel-Faucher O; Bregigeon S; Cano CE; Obry-Roguet V; Nicolino-Brunet C; Tamalet C; Dignat-George F; Poizot-Martin I
AIDS; 2015 Jul; 29(12):1505-10. PubMed ID: 26244390
[TBL] [Abstract][Full Text] [Related]
35. Correlation of immune activation during late pregnancy and early postpartum with increases in plasma HIV RNA, CD4/CD8 T cells, and serum activation markers.
Truong HM; Sim MS; Dillon M; Uittenbogaart CH; Dickover R; Plaeger SF; Bryson YJ
Clin Vaccine Immunol; 2010 Dec; 17(12):2024-8. PubMed ID: 20980480
[TBL] [Abstract][Full Text] [Related]
36. CD4(+) T-cell immunodeficiency is more dependent on immune activation than viral load in HIV-infected children on highly active antiretroviral therapy.
Resino S; Seoane E; Gutiérrez MD; León JA; Muñoz-Fernández MA
J Acquir Immune Defic Syndr; 2006 Jul; 42(3):269-76. PubMed ID: 16810122
[TBL] [Abstract][Full Text] [Related]
37. Neurocognitive dysfunction in HIV-infected youth: investigating the relationship with immune activation.
Eckard AR; Rosebush JC; O'Riordan MA; Graves CC; Alexander A; Grover AK; Lee ST; Habib JG; Ruff JH; Chahroudi A; McComsey GA
Antivir Ther; 2017; 22(8):669-680. PubMed ID: 28327462
[TBL] [Abstract][Full Text] [Related]
38. Long-term immunological response in HIV-1-infected subjects receiving potent antiretroviral therapy.
Kaufmann GR; Bloch M; Zaunders JJ; Smith D; Cooper DA
AIDS; 2000 May; 14(8):959-69. PubMed ID: 10853977
[TBL] [Abstract][Full Text] [Related]
39. Circulating interleukin-6 levels correlate with residual HIV viraemia and markers of immune dysfunction in treatment-controlled HIV-infected patients.
Bastard JP; Soulié C; Fellahi S; Haïm-Boukobza S; Simon A; Katlama C; Calvez V; Marcelin AG; Capeau J
Antivir Ther; 2012; 17(5):915-9. PubMed ID: 22436412
[TBL] [Abstract][Full Text] [Related]
40. Altered clonogenic capability and stromal cell function characterize bone marrow of HIV-infected subjects with low CD4+ T cell counts despite viral suppression during HAART.
Isgrò A; Leti W; De Santis W; Marziali M; Esposito A; Fimiani C; Luzi G; Pinti M; Cossarizza A; Aiuti F; Mezzaroma I
Clin Infect Dis; 2008 Jun; 46(12):1902-10. PubMed ID: 18462177
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
